About This Fund
Kurma Growth Opportunities Fund (KGOF) is a growth-stage and crossover life sciences fund managed by Kurma Partners, a Paris- and Munich-based investment firm and Eurazeo Group subsidiary. The fund completed its final close at €167 million in 2024, providing a dedicated late-stage vehicle to complement Kurma's earlier-stage Biofund series. KGOF is designed to invest in companies that have advanced beyond the venture stage and are positioning for significant commercial milestones, public market listings, or M&A exits in the near to medium term.
KGOF invests across the therapeutic, diagnostic, HealthTech, MedTech, and life science tools subsectors, targeting SMEs raising growth capital through late-stage private rounds, crossover financings, and public offerings in high unmet medical need areas. The fund's investment mandate is deliberately broad within life sciences—spanning therapeutics at clinical stages through diagnostics and digital health platforms—reflecting Kurma's view that growth-stage capital deployment requires flexibility across asset types and clinical modalities. Geographically, KGOF focuses primarily on European companies, with additional investment rights in existing Kurma portfolio companies as they reach scale. Investment decisions prioritise companies with validated clinical or commercial proof-of-concept and clear paths to liquidity.
Kurma Partners manages a family of specialized life sciences fund vehicles totalling approximately €1 billion in AUM as of 2026, including Biofund I through Biofund IV, Kurma Diagnostics II, and the Paris Saclay Seed Fund co-managed with Partech Ventures. The firm's track record spans the full cycle from company creation to exit: Biofund III produced acquisitions by AstraZeneca, Eli Lilly, and UniQure, establishing Kurma as a top-tier European biotech franchise. KGOF extends this franchise into the growth phase, providing continuity of capital for the firm's most mature portfolio companies while also sourcing new opportunities in later-stage European biotech.